title: Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study.
abstract: OBJECTIVE
  Weight gain is a serious side effect of atypical antipsychotics, especially in childhood. In this study, the authors examined six weight gain-related hormones in patients with childhood-onset schizophrenia (COS) after 6 weeks of clozapine treatment.
  
  
  METHODS
  Fasting serum samples for 24 patients with COS and 21 matched healthy controls (HC) were obtained. Levels of leptin, insulin, adiponectin, amylin, ghrelin, and tumor necrosis factor alpha were measured and compared between the groups. For 23 patients with COS, hormonal levels were measured at background and week 6 of clozapine treatment. Change in body mass index was correlated with levels of clozapine and changes in hormonal levels and clinical ratings.
  
  
  RESULTS
  At baseline, COS did not differ significantly from HC on any hormonal measure. Clozapine treatment was associated with significant (7.9% +/- 8.5%) increase in mean body mass index. Only leptin levels increased significantly from baseline to week 6 on clozapine (p = .003). Body mass index increase was significantly correlated with decrease in ghrelin and adiponectin and was positively correlated with clinical improvement.
  
  
  CONCLUSIONS
  This is the first study of weight gain-related hormones in children on clozapine. Hormonal changes are correlated with weight gain. How effectiveness of clozapine is linked to weight gain remains uncertain.
authors.affiliation: Child Psychiatry Branch, NIMH, NIH, Bethesda, MD, USA. sporna@intra.nimh.nih.gov
authors.forename: Alexandra L
authors.initials: AL
authors.lastname: Sporn
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Bobb
authors.forename: Nitin
authors.initials: N
authors.lastname: Gogtay
authors.forename: Hanna
authors.initials: H
authors.lastname: Stevens
authors.forename: Deanna K
authors.initials: DK
authors.lastname: Greenstein
authors.forename: Liv S
authors.initials: LS
authors.lastname: Clasen
authors.forename: Julia W
authors.initials: JW
authors.lastname: Tossell
authors.forename: Thomas
authors.initials: T
authors.lastname: Nugent
authors.forename: Peter A
authors.initials: PA
authors.lastname: Gochman
authors.forename: Wendy S
authors.initials: WS
authors.lastname: Sharp
authors.forename: Anand
authors.initials: A
authors.lastname: Mattai
authors.forename: Marge C
authors.initials: MC
authors.lastname: Lenane
authors.forename: Jack A
authors.initials: JA
authors.lastname: Yanovski
authors.forename: Judith L
authors.initials: JL
authors.lastname: Rapoport
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D015992:Body Mass Index; D002648:Child; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D006728:Hormones; D003024:Clozapine